Trial Profile

A Phase 1, open-label, single center study in healthy Japanese Han Chinese and Caucasian volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exidavnemab (Primary) ; Exidavnemab (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics

Most Recent Events

30 Aug 2024 New trial record
27 Aug 2024 According to a BioArctic AB media release, announced today that the results from two single-ascending dose phase-1 studies (M19-304 and M19-465) with exidavnemab have been published in The Journal of Clinical Pharmacology.
27 Aug 2024 Results published in a BioArctic AB media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com